Literature DB >> 21988540

Angiotensin receptor blockers are associated with a lower remodelling score of stenotic aortic valves.

Nancy Côté1, Christian Couture, Philippe Pibarot, Jean-Pierre Després, Patrick Mathieu.   

Abstract

BACKGROUND: Experimental and clinical studies have suggested that inhibitors of the renin angiotensin system (RAS) might be useful to slow the progression of valvular calcification in patients with aortic stenosis (AS).
OBJECTIVES: The aim of this study was to evaluate the relationships between the weight and tissue remodelling score of stenotic aortic valves explanted at the time of valve replacement surgery and to determine the effect of medications including angiotensin II receptor type I blockers (ARBs) and angiotensin-converting enzyme (ACE) inhibitors on these variables.
METHODS: Aortic valve and blood plasma were collected in 208 patients with AS (mean age: 69 ± 9) who underwent aortic valve replacement. Valves were weighed and the degree of valve tissue remodelling was assessed using a modified scoring system from Warren (Score: 1-4). Also, the 0-cresolphtalein complexone method was used to measure the amount of calcium within the valve cusps.
RESULTS: The mean weight of aortic valves was higher in men than in women (2·83 ± 0·09 vs. 1·91 ± 0·09 g, P < 0·0001), in patients with bicuspid vs. tricuspid valves (3·21 ± 0·15 vs. 2·23 ± 0·07 g, P < 0·0001), and in patients with higher remodelling score (score 2: 1·86 ± 0·19 g; score 3: 2·08 ± 0·12 g; score 4: 3·08 ± 0·1 g, P < 0·0001). The remodelling score was higher in men (3·35 ± 0·05 vs. 2·94 ± 0·07, P < 0·0001) and in bicuspid valves (3·38 ± 0·07 vs. 3·14 ± 0·05, P = 0·006). Both valve weight (r = 0·44, P < 0·0001) and remodelling score (r = 0·23, P = 0·002) correlated with calcium content within the aortic valve. Patients under ARBs medication (n = 47, 22·6%) had lower aortic valve weights (2·14 ± 0·13 g vs. 2·63 ± 0·09 g, P = 0·001) and remodelling scores (3·01 ± 0·09 vs. 3·26 ± 0·04, P = 0·009). On multivariate analyses, ARBs were significantly associated with a lower aortic valve remodelling score (P = 0·04) and weight (P = 0·02).
CONCLUSIONS: ARBs were associated with lower aortic valve weight and less pronounced tissue remodelling. Further studies are needed to determine if ARBs could be used as a therapeutic avenue in AS.
© 2011 The Authors. European Journal of Clinical Investigation © 2011 Stichting European Society for Clinical Investigation Journal Foundation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21988540     DOI: 10.1111/j.1365-2362.2011.02522.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  18 in total

1.  Paradoxical low-flow, low-gradient aortic stenosis despite preserved left ventricular ejection fraction: new insights from weights of operatively excised aortic valves.

Authors:  Marie-Annick Clavel; Nancy Côté; Patrick Mathieu; Jean G Dumesnil; Audrey Audet; Andrée Pépin; Christian Couture; Dominique Fournier; Sylvain Trahan; Sylvain Pagé; Philippe Pibarot
Journal:  Eur Heart J       Date:  2014-04-21       Impact factor: 29.983

Review 2.  Potential drug targets for calcific aortic valve disease.

Authors:  Joshua D Hutcheson; Elena Aikawa; W David Merryman
Journal:  Nat Rev Cardiol       Date:  2014-01-21       Impact factor: 32.419

Review 3.  Cardiac tissue remodeling in healthy aging: the road to pathology.

Authors:  Evan Tracy; Gabrielle Rowe; Amanda J LeBlanc
Journal:  Am J Physiol Cell Physiol       Date:  2020-05-20       Impact factor: 4.249

Review 4.  Current management of calcific aortic stenosis.

Authors:  Brian R Lindman; Robert O Bonow; Catherine M Otto
Journal:  Circ Res       Date:  2013-07-05       Impact factor: 17.367

Review 5.  Cellular mechanisms of aortic valve calcification.

Authors:  Jane A Leopold
Journal:  Circ Cardiovasc Interv       Date:  2012-08-01       Impact factor: 6.546

6.  Systolic hypertension and progression of aortic valve calcification in patients with aortic stenosis: results from the PROGRESSA study.

Authors:  Lionel Tastet; Romain Capoulade; Marie-Annick Clavel; Éric Larose; Mylène Shen; Abdellaziz Dahou; Marie Arsenault; Patrick Mathieu; Élisabeth Bédard; Jean G Dumesnil; Alexe Tremblay; Yohan Bossé; Jean-Pierre Després; Philippe Pibarot
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2016-02-18       Impact factor: 6.875

7.  Calcific aortic valve disease: from molecular and cellular mechanisms to medical therapy.

Authors:  Simon Kraler; Mark C Blaser; Elena Aikawa; Giovanni G Camici; Thomas F Lüscher
Journal:  Eur Heart J       Date:  2022-02-12       Impact factor: 29.983

Review 8.  Calcific aortic stenosis.

Authors:  Brian R Lindman; Marie-Annick Clavel; Patrick Mathieu; Bernard Iung; Patrizio Lancellotti; Catherine M Otto; Philippe Pibarot
Journal:  Nat Rev Dis Primers       Date:  2016-03-03       Impact factor: 52.329

9.  Proteinuria is an independent predictor of rapid progression of mild to moderate aortic stenosis in patients with preserved renal function.

Authors:  You-Jung Choi; Jun-Bean Park; In-Chang Hwang; Seung-Pyo Lee; Hyung-Kwan Kim; Yong-Jin Kim; Dae-Won Sohn
Journal:  Int J Cardiovasc Imaging       Date:  2018-10-20       Impact factor: 2.357

10.  5-HT(2B) antagonism arrests non-canonical TGF-β1-induced valvular myofibroblast differentiation.

Authors:  Joshua D Hutcheson; Larisa M Ryzhova; Vincent Setola; W David Merryman
Journal:  J Mol Cell Cardiol       Date:  2012-08-23       Impact factor: 5.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.